全文获取类型
收费全文 | 17810篇 |
免费 | 1403篇 |
国内免费 | 126篇 |
专业分类
耳鼻咽喉 | 113篇 |
儿科学 | 594篇 |
妇产科学 | 564篇 |
基础医学 | 2428篇 |
口腔科学 | 349篇 |
临床医学 | 1741篇 |
内科学 | 3355篇 |
皮肤病学 | 301篇 |
神经病学 | 1339篇 |
特种医学 | 573篇 |
外科学 | 2694篇 |
综合类 | 739篇 |
一般理论 | 14篇 |
预防医学 | 1358篇 |
眼科学 | 502篇 |
药学 | 1031篇 |
1篇 | |
中国医学 | 85篇 |
肿瘤学 | 1558篇 |
出版年
2023年 | 182篇 |
2022年 | 99篇 |
2021年 | 471篇 |
2020年 | 362篇 |
2019年 | 509篇 |
2018年 | 530篇 |
2017年 | 389篇 |
2016年 | 435篇 |
2015年 | 515篇 |
2014年 | 637篇 |
2013年 | 799篇 |
2012年 | 1268篇 |
2011年 | 1285篇 |
2010年 | 752篇 |
2009年 | 655篇 |
2008年 | 994篇 |
2007年 | 963篇 |
2006年 | 978篇 |
2005年 | 977篇 |
2004年 | 930篇 |
2003年 | 833篇 |
2002年 | 787篇 |
2001年 | 558篇 |
2000年 | 446篇 |
1999年 | 373篇 |
1998年 | 136篇 |
1997年 | 130篇 |
1996年 | 115篇 |
1995年 | 113篇 |
1994年 | 94篇 |
1993年 | 78篇 |
1992年 | 186篇 |
1991年 | 169篇 |
1990年 | 176篇 |
1989年 | 180篇 |
1988年 | 148篇 |
1987年 | 145篇 |
1986年 | 128篇 |
1985年 | 94篇 |
1984年 | 74篇 |
1983年 | 63篇 |
1982年 | 34篇 |
1981年 | 50篇 |
1980年 | 46篇 |
1979年 | 62篇 |
1978年 | 50篇 |
1977年 | 43篇 |
1976年 | 37篇 |
1975年 | 32篇 |
1973年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Yunbao Xu Mengting Zhang Jiaying Zhang Derry Minyao Ng Xiaoxiao Chen Yuexiu Si Yetan Shi Xiangyuan Li Danyi Mao Lu Yang 《Taiwanese journal of obstetrics & gynecology》2021,60(3):433-441
Cervical cancer is a global health challenge in women. Neoadjuvant chemotherapy (NACT) is a recent prospect for alternative cervical cancer treatments. This study investigated the efficacy of NACT against resectable cervical cancer based on the medium and long-term survival of patients with the disease. We searched through PubMed, Web of Science, EBSCO and Cochrane Library for relevant reports published by June 2020. The primary outcomes were 3-year and 5-year progression-free survival (PFS) and overall survival (OS) of patients with resectable cervical cancer. Overall, 22 publications encompassing 5627 patients fulfilled the inclusion criteria. We found NACT not to affect both 3-year PFS and OS as well as 5-year PFS of patients with resectable cervical cancer. However, NACT significantly improves the 5-year OS of patients with resectable cervical cancer (HR = 0.83, 95% CI: 0.73–0.94, p = 0.013). Subgroup analysis (RCTs, non-RCTs, NACT + surgery + AT vs. surgery + AT, NACT + surgery + AT vs. CCRT/RT/CRT) further revealed NACT had no significant effect on 5-year PFS of patients with resectable cervical cancer, converse to the 5-year OS subgroup analysis, which validated the beneficial effect of NACT in patients with resectable cervical cancer. In addition, the effect of NACT was most significant in the non-RCTs subgroup (p = 0.012). NACT may improve the long-term prognosis of patients with resectable cervical cancer. However, further large-scale multicenter studies are needed to validate this finding. 相似文献
2.
Pauline A. J. Mendelaar Jaco Kraan Mai Van Leonie L. Zeune Leon W. M. M. Terstappen Esther Oomende Hoop John W. M. Martens Stefan Sleijfer 《Molecular oncology》2021,15(1):116
Circulating tumor cells (CTCs) in the blood of cancer patients are of high clinical relevance. Since detection and isolation of CTCs often rely on cell dimensions, knowledge of their size is key. We analyzed the median CTC size in a large cohort of breast (BC), prostate (PC), colorectal (CRC), and bladder (BLC) cancer patients. Images of patient‐derived CTCs acquired on cartridges of the FDA‐cleared CellSearch® method were retrospectively collected and automatically re‐analyzed using the accept software package. The median CTC diameter (μm) was computed per tumor type. The size differences between the different tumor types and references (tumor cell lines and leukocytes) were nonparametrically tested. A total of 1962 CellSearch® cartridges containing 71 612 CTCs were included. In BC, the median computed diameter (CD) of patient‐derived CTCs was 12.4 μm vs 18.4 μm for cultured cell line cells. For PC, CDs were 10.3 μm for CTCs vs 20.7 μm for cultured cell line cells. CDs for CTCs of CRC and BLC were 7.5 μm and 8.6 μm, respectively. Finally, leukocytes were 9.4 μm. CTC size differed statistically significantly between the four tumor types and between CTCs and the reference data. CTC size differences between tumor types are striking and CTCs are smaller than cell line tumor cells, whose size is often used as reference when developing CTC analysis methods. Based on our data, we suggest that the size of CTCs matters and should be kept in mind when designing and optimizing size‐based isolation methods.
Abbreviations
- ACCEPT
- Automated CTC Classification, Enumeration, and PhenoTyping software
- BC
- breast cancer
- BLC
- bladder cancer
- CD
- computed diameter
- CEL
- cultured tumor cell (cell line)
- CK
- cytokeratin
- CRC
- colorectal cancer
- CTC‐L
- circulating tumor cells derived from cerebrospinal fluid (liquor)
- CTCs
- circulating tumor cells
- DAPI
- 4′6‐diamidino‐2‐phenylindole
- EMT
- epithelial–mesenchymal transition
- EpCAM
- epithelial cell adhesion molecule
- IQR
- interquartile range
- KW test
- Kruskal–Wallis test
- MWU test
- Mann–Whitney U test
- NCR
- nucleus/cytoplasm ratio
- P2A
- perimeter to area
- PC
- prostate cancer
- TIF
- tagged Image Format files
- TXT
- text file
- μm
- micrometer
- µm2
- square micrometers
3.
4.
Sarah Hallas Andrea Nelson Susan O'Meara Una Adderley Pauline Meskell Jane Nixon Aonghus O'Loughlin Sebastian Probst Wael Tawfick Thomas Wild Georgina Gethin 《Journal of tissue viability》2021,30(3):317-323
BackgroundA venous leg ulcer is a chronic leg wound caused by poor venous blood circulation in the lower limbs. It is a recurring condition causing pain, malodour, reduced mobility, and depression. Randomised controlled trials evaluating treatments for venous leg ulcers provide important evidence to inform clinical decision-making. However, for findings to be useful, outcomes need to be clinically meaningful, consistently reported across trials, and fully reported. Research has identified the large number of outcomes reported in venous leg ulcer trials, impacting both synthesis of results, and clinical decision-making. To address this, a core outcome set will be developed. A core outcome set is an agreed standardised set of outcomes which should be, as a minimum, measured and reported in all trials which evaluate treatment effectiveness for a given indication. A core outcome set has the potential to reduce research waste, improve the utility of RCTs, reduce reporting bias, facilitate treatment comparisons across different sources of evidence and expedite the production of systematic reviews, meta-analyses and evidence-based clinical guidelines.AimThe aim of this project is to develop a core outcome set for research evaluating the effectiveness of interventions for treating venous leg ulceration.MethodsThrough a scoping review of the literature on venous leg ulceration, we will firstly identify a list of candidate outcome domains (broad categories in relation to what is being measured) from randomised controlled trials and qualitative research, and outcomes (specific methods in relation to what is being measured). In two further stages, we will use the resulting lists of outcome domains and outcomes to design two online surveys. A range of stakeholders will be invited to participate in the surveys and they will be asked to indicate which outcome domains and outcomes are most important and should be considered as core in future research reports. 相似文献
5.
6.
7.
8.
9.